AngioDynamics, Inc. ANGO R2K
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -2.6% CAGR over 5 years.
- Earnings shrank at -9.3% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ANGO AngioDynamics, Inc. R2K | 11.48 | - | $474.34M | - | -11.80% | -17.47% | -2.57% | -9.35% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Aug 2015 | Nov 2015 | Feb 2016 | May 2016 | Aug 2016 | Nov 2016 | Feb 2017 | May 2017 | Aug 2017 | Nov 2017 | Feb 2018 | May 2018 | Aug 2018 | Nov 2018 | Feb 2019 | May 2019 | Aug 2019 | Nov 2019 | Feb 2020 | May 2020 | Aug 2020 | Nov 2020 | Feb 2021 | Aug 2021 | Nov 2021 | Feb 2022 | May 2022 | Aug 2022 | Nov 2022 | Feb 2023 | Aug 2023 | Nov 2023 | Feb 2024 | Aug 2024 | Nov 2024 | Feb 2025 | May 2025 | Aug 2025 | Nov 2025 | Feb 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 70.22M | 72.77M | 71.18M | 76.97M | 78.28M | 73.97M | - | 81.54M | 85.43M | 80.71M | 78.68M | 79.07M | 75.18M | - | - | 72.00M | 80.16M | 75.71M | 79.43M | 78.42M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 33.15M | 37.94M | 33.85M | 34.65M | 36.94M |
| Gross Profit | 43.37M | 45.88M | 43.53M | 41.53M | 45.03M | 45.01M | 43.79M | 42.34M | 33.04M | 34.70M | 37.50M | 38.62M | 35.95M | 40.55M | 38.16M | 41.33M | 38.22M | 41.54M | 40.30M | 30.21M | 35.76M | 40.17M | 38.53M | 40.14M | 40.55M | 38.58M | - | 42.30M | 45.08M | 40.50M | 40.06M | 40.26M | 35.86M | - | - | 38.86M | 42.22M | 41.86M | 44.78M | 41.48M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.51M | 45.85M | 49.76M | 47.27M | 47.91M |
| Operating Income | 212.00K | 565.00K | 1.97M | - | 3.57M | 15.59M | 5.14M | - | 140.00K | 1.12M | 4.86M | - | -6.13M | -2.53M | -3.67M | - | -828.00K | -3.42M | -6.24M | - | -5.12M | -4.84M | -3.74M | -8.10M | -8.68M | -5.29M | - | -13.30M | -8.12M | -8.93M | 35.03M | -13.12M | -199.90M | - | - | -6.65M | -3.63M | -7.90M | -2.49M | -6.43M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -329.00K | 2.20M | -1.88M | 3.26M | -838.00K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.41M | -6.11M | -10.84M | -6.36M | -8.07M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.00K | -60.00K | 65.00K | -5.00K | 12.00K |
| Net Income | -775.00K | -334.00K | 594.00K | -43.08M | 1.30M | 13.73M | 2.89M | -12.91M | -35.00K | 249.00K | 14.02M | 2.10M | -469.00K | 2.14M | 796.00K | 58.87M | -1.27M | -2.74M | -5.71M | -157.07M | -4.27M | -4.27M | -3.54M | -6.97M | -8.35M | -4.96M | -13.00M | -13.00M | -8.49M | -9.48M | 45.88M | -29.05M | -187.74M | - | - | -4.41M | -6.05M | -10.90M | -6.35M | -8.08M |
| Diluted EPS | -0.02 | -0.01 | 0.02 | -1.19 | 0.04 | 0.37 | 0.08 | -0.35 | 0.00 | 0.01 | 0.37 | 0.06 | -0.01 | 0.06 | 0.02 | 1.54 | -0.03 | -0.07 | -0.15 | -4.14 | -0.11 | -0.11 | -0.09 | -0.18 | -0.21 | -0.13 | - | -0.33 | -0.21 | -0.24 | 1.15 | -0.72 | -4.67 | - | - | -0.11 | -0.15 | -0.26 | -0.15 | -0.19 |
| R&D Expense | 6.13M | 6.18M | 5.81M | - | 6.71M | 5.91M | 5.95M | - | 6.44M | 6.11M | 6.46M | - | 7.37M | 7.08M | 6.92M | - | 6.29M | 7.76M | 8.39M | - | 9.01M | 9.71M | 8.56M | 7.39M | 8.20M | 7.28M | - | 8.33M | 6.84M | 6.85M | 7.94M | 8.66M | 8.19M | 6.29M | 6.43M | 6.91M | - | 6.42M | 7.77M | 7.08M |
Profit & Loss (Annual)
Figures in USD.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 264.16M | - | 316.22M | 338.75M | 303.91M | 292.50M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 150.49M | 164.51M | 149.22M | 134.79M |
| Gross Profit | 126.97M | 125.57M | 125.31M | 168.51M | 180.17M | 175.80M | 174.32M | 143.95M | 143.86M | 156.00M | 150.27M | - | 165.73M | 174.25M | 154.70M | 157.71M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 183.95M | 192.93M | 188.54M | 181.77M |
| Operating Income | 20.87M | 11.90M | -5.24M | 5.24M | 10.49M | -3.45M | 1.02M | -11.18M | -14.17M | -9.40M | -167.10M | - | -18.22M | -18.68M | -33.84M | -24.06M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | 11.13M | 12.19M | -6.13M | 1.74M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 861.00K | 688.00K | 2.70M | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -29.95M | -54.44M | -191.64M | -34.03M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | -3.40M | -2.00M | -7.29M | -39.00K |
| Net Income | 12.31M | 8.08M | -5.33M | -1.05M | 2.35M | -3.39M | -43.59M | 5.01M | 16.34M | 61.34M | -166.79M | - | -26.55M | -52.44M | -184.35M | -33.99M |
| Diluted EPS | 0.50 | 0.32 | -0.20 | -0.03 | 0.07 | -0.09 | -1.21 | 0.14 | 0.44 | 1.64 | -4.39 | - | -0.68 | -1.33 | -4.59 | -0.83 |
| R&D Expense | 19.27M | 21.37M | 20.51M | 26.09M | 28.12M | 26.59M | 25.05M | 24.15M | 24.34M | 28.26M | 29.68M | 36.39M | 30.74M | 29.88M | 31.51M | 26.22M |
Compounded Sales Growth
| 5 Years: | -2.57% |
| 1 Year: | 8.90% |
Compounded Profit Growth
| 5 Years: | -9.35% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +12.55% |
| 6 Months: | -7.42% |
| 3 Months: | +0.35% |
| 1 Month: | +7.69% |
Balance Sheet (Annual)
Figures in USD.
| Metric | May 2009 | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | Aug 2014 | Nov 2014 | Feb 2015 | May 2015 | Aug 2015 | Nov 2015 | Feb 2016 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 437.31M | 719.90M | 790.56M | 798.58M | 796.17M | 798.73M | 783.39M | 773.06M | 772.00M | 760.44M | 753.61M | 726.19M | 707.96M | 705.47M | 836.44M | 594.21M | - | 552.75M | 532.64M | 317.67M | 280.14M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 143.34M | 163.54M | 193.25M | 168.32M |
| Cash & Equivalents | 27.91M | 58.76M | 45.98M | 23.74M | 16.11M | 18.39M | - | - | - | 18.39M | - | - | - | 32.33M | 47.54M | 74.10M | 227.64M | 54.44M | - | 28.82M | 44.62M | 76.06M | 55.89M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 51.39M | 55.33M | 60.62M | 62.01M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.30M | 52.83M | 43.61M | 42.89M |
| Total Liabilities | - | - | 31.68M | 196.60M | 264.24M | 261.69M | 256.58M | 255.49M | 239.82M | 227.96M | 224.82M | 212.72M | 202.82M | 218.97M | 192.93M | 162.88M | 221.62M | 139.34M | - | 128.26M | 154.34M | 112.08M | 97.17M |
| Current Liabilities | - | - | 25.40M | 53.77M | 62.92M | 65.94M | 63.35M | 57.10M | 59.50M | 60.52M | 60.80M | 60.09M | 61.63M | 66.73M | 71.52M | 57.30M | 73.30M | 51.45M | - | 74.32M | 83.83M | 91.16M | 76.20M |
| Long Term Debt | - | - | 6.28M | 142.50M | 135.00M | 137.66M | - | - | - | - | - | - | - | - | 91.32M | 86.62M | 124.41M | - | 20.00M | 25.00M | 49.82M | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.00M | 33.78M | 64.58M | 4.73M | - |
| Total Equity | 372.19M | 391.35M | 405.64M | 523.31M | 526.32M | 536.88M | 539.59M | 543.24M | 543.57M | 545.10M | 547.18M | 547.73M | 550.80M | 507.23M | 515.03M | 542.60M | 614.82M | 454.87M | - | 424.49M | 378.30M | 205.59M | 182.97M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.54M | 39.98M | 40.80M | 41.61M |
Cash Flows (Annual)
Figures in USD.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 39.96M | 33.87M | 11.60M | 26.65M | 24.68M | 25.68M | 45.22M | 55.74M | 41.29M | 37.44M | -14.55M | - | -7.19M | 78.00K | -28.16M | -10.13M |
| Investing Cash Flow | -11.78M | -48.62M | -176.23M | -22.24M | -16.45M | -12.74M | -7.57M | -2.55M | -3.66M | 82.55M | -63.34M | - | -19.31M | -9.75M | 123.72M | -10.18M |
| Financing Cash Flow | 2.72M | 1.92M | 142.34M | -6.29M | -14.02M | -10.46M | -23.66M | -37.98M | -11.55M | 33.93M | -95.24M | - | 7.68M | 25.42M | -64.25M | -255.00K |
| Capital Expenditure | -5.04M | -2.96M | -2.49M | -12.12M | -11.17M | -11.38M | -2.33M | -3.00M | -2.39M | -3.12M | -7.24M | - | -4.30M | -4.35M | -5.77M | -4.46M |
| Free Cash Flow | 34.92M | 30.91M | 9.11M | 14.53M | 13.51M | 14.30M | 42.89M | 52.74M | 38.90M | 34.32M | -21.79M | - | -11.49M | -4.27M | -33.93M | -14.59M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -18.82M | 15.75M | 31.31M | -20.56M |
| Share Buybacks | - | - | 2.10M | 0 | 0 | 0 | 0 | 13.56M | 0 | 0 | - | - | - | 0 | 0 | 1.67M |
| Dividends Paid | - | - | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | 56.9% | - | 52.4% | 51.4% | 50.9% | 53.9% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | -63.3% | - | -5.8% | -5.5% | -11.1% | -8.2% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | -63.1% | - | -8.4% | -15.5% | -60.7% | -11.6% |
| ROE % | 3.1% | 2.0% | -1.0% | -0.2% | 0.4% | -0.6% | -8.6% | 1.0% | 3.0% | 10.0% | -36.7% | - | -6.3% | -13.9% | -89.7% | -18.6% |
| ROCE % | - | 2.9% | -0.8% | 0.7% | 1.4% | -0.5% | 0.2% | -1.8% | -2.2% | -1.2% | -30.8% | - | -3.8% | -4.2% | -14.9% | -11.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.92% | 3.69M | $42.31M |
| 2 | Point72 Asset Management, L.P. | 7.70% | 3.18M | $36.53M |
| 3 | Systematic Financial Management, L.P. | 5.94% | 2.45M | $28.17M |
| 4 | Broadfin Holdings LLC | 5.01% | 2.07M | $23.76M |
| 5 | Armistice Capital, LLC | 4.52% | 1.87M | $21.46M |
| 6 | Vanguard Capital Management LLC | 4.18% | 1.73M | $19.82M |
| 7 | Royce & Associates LP | 3.70% | 1.53M | $17.55M |
| 8 | Weber Capital Management LLC /ADV | 3.32% | 1.37M | $15.76M |
| 9 | State Street Corporation | 3.23% | 1.33M | $15.31M |
| 10 | Bastion Asset Management Inc. | 3.18% | 1.31M | $15.07M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ANGO